NeOnc receives FDA feedback on NEO212 tablet transition

NeOnc Technologies received detailed FDA feedback regarding the Chemistry, Manufacturing and Controls for its NEO212 candidate, including actionable steps for a tablet formulation transition. The constructive guidance allows the company to proceed with a staged stability program, supporting the advancement of its late-stage clinical development.